MoonLake Immunotherapeutics Debt-to-equity in % from Q3 2021 to Q3 2025

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: MoonLake Immunotherapeutics quarterly Debt-to-equity history and growth rate from Q3 2021 to Q3 2025.
MoonLake Immunotherapeutics Debt-to-equity for the quarter ending September 30, 2025 was 23.3 %, a 665% increase year-over-year.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Growth (%)

MoonLake Immunotherapeutics Quarterly Debt-to-equity (%)

Period	Value	YoY Chg	Change %	Date
Q3 2025	23.3	+20.2	+665%	Sep 30, 2025
Q2 2025	14.6	+12.1	+478%	Jun 30, 2025
Q1 2025	8.63	+6.43	+293%	Mar 31, 2025
Q4 2024	3.69	+1.02	+38.2%	Dec 31, 2024
Q3 2024	3.05	-0.32	-9.51%	Sep 30, 2024
Q2 2024	2.53	-2.08	-45.2%	Jun 30, 2024
Q1 2024	2.2	-10	-82%	Mar 31, 2024
Q4 2023	2.67	-114	-97.7%	Dec 31, 2023
Q3 2023	3.37	-178	-98.1%	Sep 30, 2023
Q2 2023	4.61	-329	-98.6%	Jun 30, 2023
Q1 2023	12.2	-1.83K	-99.3%	Mar 31, 2023
Q4 2022	117	+370		Dec 31, 2022
Q3 2022	181	+554		Sep 30, 2022
Q2 2022	333			Jun 30, 2022
Q1 2022	1.85K			Mar 31, 2022
Q4 2021	-253			Dec 31, 2021
Q3 2021	-373			Sep 30, 2021

* An asterisk sign (*) next to the value indicates that the value is likely invalid.